NDAORALTABLET, EXTENDED RELEASE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
KLOR-CON (potassium chloride) by Ascentage Pharma is tissues. First approved in 1986.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOR-CON is an oral extended-release tablet formulation of potassium chloride, a naturally occurring electrolyte essential for maintaining cellular function, nerve impulse transmission, and cardiac/skeletal muscle contraction. It is indicated for the treatment of hypokalemia (low potassium levels) in patients without metabolic alkalosis and for managing potassium depletion in digitalis intoxication. The drug works by replenishing intracellular potassium stores to restore the normal plasma concentration range of 3.5–5 mEq/L, which is critical for normal cardiac and renal function.
$0.0BPart D
Mechanism of Action
tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KLOR-CON's mature, commoditized market position creates limited career opportunities, primarily in generic product management, supply chain optimization, and cost-containment roles rather than promotional activities. Currently, zero job openings are linked to this product, reflecting low commercial priority. Professionals working on this product require expertise in generic market dynamics, payer negotiations, and manufacturing efficiency rather than clinical differentiation or patient advocacy.
Worked on KLOR-CON at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.